| Project/Area Number |
22501018
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor biology
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATAGIRI Masato 北里大学, 医療衛生学部, 教授 (50152674)
MAJIMA Masataka 北里大学, 医学部, 教授 (70181641)
MATSUMOTO Kazumasa 北里大学, 医学部, 講師 (70306603)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | リンパ管新生 / 細胞療法 / 癌転移 / リンバ管新生 |
|---|
| Research Abstract |
The suppressive effects of lymphangiogenesis using mouse soluble vascular endothelial growth factor (VEGF)-C receptor (sVegfr-2) cDNA introduced mouse embryonic fibroblast cells (C57-sVegfr-2) and Lweis lung carcinoma cells (LLC-sVegfr-2) were evaluated. The production of svegfr-2 and strong binding effect with VEGF-C in the supernatant of C57-sVegfr-2 were verified in vitro by Western blotting and immune -precipitation, respectively. The lymphangiogenesis was significantly reduced in primary lesion, followed by inoculation of LLC-sVegfr-2 into C57 mice, in vivo
|
